UroGen Pharma Ltd.
NASDAQUroGen Pharma heads into its May 11 earnings report with short sellers pulling back even as the stock's structural bear case remains firmly intact. The most striking feature of the past month is the divergence between price and positioning. The stock has climbed 27% over the past month to $23.83, yet short interest has moved in the opposite direction — falling roughly 7% over the…
Snapshot as of 7 May 2026
UroGen Pharma heads into its May 11 earnings report with short sellers pulling back even as the stock's structural bear case remains firmly intact. The most striking feature of the past month is the divergence between…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for URGN — free to start on ORTEX.
Sign up for free →Open URGN on ORTEX